Skip to content

G&A at other companies

ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$8.49M+54.9%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$37.59M-8.4%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$29M+3.6%
Bicara Therapeutics logo
Bicara TherapeuticsBCAX
$12.74M+70.9%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
$28.24M+137%
Viking Therapeutics logo
Viking TherapeuticsVKTX
$13.98M-0.7%

Other financials

Income statement

See full
Operating income-$42.0M-31.9%
Net income-$39.3M-39.6%
EPS (diluted)-$0.64-36.2%

Balance sheet

See full
Cash & equivalents$85.0M-15.7%
Total debt$5.7M-6.9%
Total equity$387.6M+19.8%
Total assets$412.0M+20.0%

Cash flow

See full
Operating cash flow-$32.6M-27.9%
CapEx$88.0K+529%
Free cash flow-$32.7M-28.2%

Valuation

See full
Market cap$1.81B+318%
Enterprise value$1.73B+397%

Returns & leverage

See full
Return on equity-36.9%+21.1pp
Debt / equity0.0×
Current ratio20.5×-2.3×

Where this comes from

Reported directly by Tyra Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Tyra Biosciences, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tyra Biosciences, Inc.'s g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tyra Biosciences, Inc.'s G&A?
Tyra Biosciences, Inc. (TYRA) reported G&A of $8.53M in Q1 2026.
How has Tyra Biosciences, Inc.'s G&A changed year-over-year?
Tyra Biosciences, Inc.'s G&A increased by 23.8% year-over-year, from $6.89M to $8.53M.
What is the long-term trend for Tyra Biosciences, Inc.'s G&A?
Over 4 years (2021 to 2025), Tyra Biosciences, Inc.'s G&A has grown at a 51.6% compound annual growth rate (CAGR), from $5.65M to $29.83M.
What does G&A mean?
Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.